About IMVT-1402

An anti-FcRn investigational therapy

At Immunovant, we are pursuing a patient-focused development approach to meet the complex and variable needs of people with autoimmune disease.



IMVT-1402

Novel, fully human, monoclonal antibody inhibiting FcRn-mediated recycling of immunoglobulin G (IgG)

IMVT-1402 has a combination of **potentially best-in-class attributes** not seen with other anti-FcRns:

Deep dose-dependent IgG reduction, based on initial Phase 1 data[1]

Favorable analyte profile with no or minimal effect on albumin and LDL, supported by initial Phase 1 data[1]

Formulated for **subcutaneous injection** that may enable self-adminstration at home

These attributes may support tailored and chronic dosing to address the symptoms of autoimmune disease across disease stage and severity.

Addressing unmet needs

Immunovant is committed to initiating a broad set of late-stage clinical programs for IMVT-1402 in several therapeutic areas, including endocrinology and neurology.

4-5

By March 31, 2025:* Initiate 4-5 potentially registrational programs

10

By March 31, 2026:* Initiate studies in a total of 10 indications

* Indications #1 through #5 will be potentially registrational programs. Indications #6 through #10 may be proof-of-concept or potentially registrational programs.

Learn more about our goal of reframing expectations in autoimmune disease at **Immunovant.com**

Reference: 1. IMVT-1402 Phase 1 single-ascending dose (SAD) and 300 mg subcutaneous multiple ascending dose (MAD) topline results. Available at: https://www.immunovant.com/investors/news-events/press-releases/detail/51/immunovant-announces-positive-initial-imvt-1402-phase-1-sad

IMMUNOVANT®